CNS Pharmaceuticals Stock Price, News & Analysis

CNS Pharmaceuticals (NASDAQ: CNSP) announced the completion of the manufacturing process for its lead drug candidate, Berubicin, aimed at treating glioblastoma multiforme (GBM). This milestone is crucial for filing an Investigational New Drug (IND) application in Q4 2020 and initiating a Phase 2 trial in the U.S. in Q1 2021. The company has engaged various partners for trial preparations and received Orphan Drug Designation from the FDA, potentially leading to market exclusivity. The dual-track manufacturing strategy also aims to mitigate COVID-19-related delays.

CNS Pharmaceuticals (NASDAQ: CNSP) recently featured a segment on glioblastoma in "Behind the Mystery," aired on Lifetime TV. The segment, which aired on October 12, 2020, showcased the story of a glioblastoma patient and insights from CNS's Scientific Advisory Board member, Dr. Sigmund Hsu. Approximately 13,000 new glioblastoma cases are diagnosed annually in the U.S., making it one of the most aggressive brain cancers. CNS is committed to developing treatments for this disease, with a Phase 2 clinical trial of its lead drug, berubicin, planned for late 2020.

CNS Pharmaceuticals (NASDAQ: CNSP) announced that its European manufacturer, BSP Pharmaceuticals, has started producing its lead drug candidate, Berubicin, for treating glioblastoma multiforme (GBM), a lethal brain cancer. CEO John Climaco highlighted significant progress towards filing an IND by the end of Q4 2020 and initiating a U.S. Phase 2 trial in Q1 2021. The company implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks. Additionally, the FDA granted Berubicin Orphan Drug Designation, which may provide the company with market exclusivity upon approval.

CNS Pharmaceuticals (NASDAQ: CNSP) announced a critical achievement in the manufacturing of Berubicin, its lead cancer treatment. Partner NCK A/S has received a Certificate of Analysis for the Active Pharma Ingredient, which allows for large-scale production. This development is expected to ensure drug availability for upcoming Phase 2 clinical trials for glioblastoma, anticipated to start in Q1 2021. CNS holds exclusive rights to Berubicin and aims to advance treatment options for aggressive brain cancers, following promising earlier trial results.

CNS Pharmaceuticals (NASDAQ: CNSP) has partnered with Image Analysis Group (IAG) to enhance imaging services for its upcoming Berubicin clinical trials. The partnership aims to leverage IAG's advanced AI-driven methodologies for real-time patient response analysis during the trials focused on glioblastoma multiforme (GBM). CNS anticipates launching Phase II trials of Berubicin in adults by early 2021. Previous Phase 1 trials showed a 44% disease control rate, though results may not guarantee future efficacy. This collaboration represents a significant step in CNS's preparation for clinical advancements.

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 10:00 AM EDT. The company is focused on developing treatments for central nervous system cancers, with its lead candidate, Berubicin, showing promising results in a completed Phase 1 trial for glioblastoma multiforme. A replay of the presentation will be available on the company’s website for 90 days following the event.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16, 2020, at 9:30 AM EDT. The conference will feature management holding 1-on-1 meetings with investors. CNS is focused on developing treatments for central nervous system cancers. Its lead drug candidate, Berubicin, targets glioblastoma multiforme, with a promising Phase 1 trial showing a 44% disease control rate. A Phase 2 trial in the U.S. is expected to commence by the end of 2020.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced advancements in the U.S. manufacturing of Berubicin, its lead drug candidate for treating CNS cancers. Engaging Pharmaceutics International, Inc. and BSP Pharmaceuticals, the company aims to mitigate COVID-19-related risks. Key milestones include completed synthesis of the active pharmaceutical ingredient (API) and a successful laboratory simulation of the lyophilization cycle. The company anticipates starting Berubicin production in Q3 2020 and plans to submit an IND to the FDA in Q4 2020, following recent achievements in clinical trial preparations.

CNS Pharmaceuticals (NASDAQ: CNSP) announced the appointment of Dr. Patrick Wen, a neurology professor at Harvard Medical School and director at Dana-Farber Cancer Institute, to its Science Advisory Board. Dr. Wen's expertise in neuro-oncology is expected to enhance CNS's efforts in advancing its lead drug candidate, Berubicin, targeting glioblastoma. The company is preparing for Phase I pediatric and Phase II adult trials in Poland and the U.S. Additionally, CNS has engaged Pharmaceutics International and BSP Pharmaceuticals for Berubicin production, ensuring localized availability for clinical use.